Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,047 matching trials from the live ClinicalTrials.gov search.
Conditions
Peritoneal Cavity Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, cytoreductive surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
366 Days to 46 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
145
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
Conditions
Kidney Transplant Recipients
Interventions
Multivitamin, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Conditions
Childhood Langerhans Cell Histiocytosis
Interventions
leucovorin calcium, methotrexate, prednisolone, vinblastine sulfate
Drug
Lead sponsor
Histiocyte Society
Other
Eligibility
Up to 17 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
4
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Urinary Tract Infections
Interventions
Antibiotic, Next Gen
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Bevacizumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Terminated Phase 2 Interventional Results available

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

NCT01359007
Conditions
Adenocarcinoma of Pancreas
Interventions
Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Colorectal Cancer
Interventions
leucovorin calcium, tegafur-uracil, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Conditions
Colorectal Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
14
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 11 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation

NCT01063049
Conditions
Preparation for Colonoscopy
Interventions
Gatorade/Miralax, NuLytely, Bisacodyl, Placebo
Drug
Lead sponsor
Gastroenterology Services, Ltd.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Downers Grove, Illinois
Conditions
Lung Cancer
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Results available

Alii Supplement Study

NCT07271316
Conditions
Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease, Mood Swings, Energy
Interventions
Alii Supplement
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Panitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine, Quality-of-Life Assessment, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 1Phase 2 Interventional Results available

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NCT03563157
Conditions
Colorectal Cancer Metastatic, mCRC
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Recruiting No phase listed Observational Accepts healthy volunteers

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

NCT05732623
Conditions
Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Behavioral
Lead sponsor
San Raffaele University
Other
Eligibility
18 Years to 49 Years
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2035
U.S. locations
2
States / cities
Denver, Colorado • Chicago, Illinois
Conditions
Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, leucovorin, Glucarpidase
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more
Conditions
Gastric Cancer
Interventions
5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more